Chilton Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Chilton Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9	Closed	-$9.46K	–	656
2024 Q3	$9.46K	Sell	9 -11	-55%	-$12.2K	﹤0.01%	489
2024 Q2	$21K	Buy	20 +6	+43%	+$5.82K	﹤0.01%	445
2024 Q1	$13.5K	Buy	+14	New	+$13.3K	﹤0.01%	457
2022 Q3	–	Sell	-10	Closed	-$6K	–	534
2022 Q2	$6K	Buy	+10	New	+$6.5K	﹤0.01%	526
2022 Q1	–	Sell	-209	Closed	-$132K	–	532
2021 Q4	$132K	Buy	+209	New	+$129K	0.01%	252
2016 Q1	–	Sell	-380	Closed	-$206K	–	171
2015 Q4	$206K	Buy	+380	New	+$206K	0.02%	148

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Chilton Capital Management's REGN Position: Q4 2024 in Review

Chilton Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 9 shares — an estimated $9.46K sold.

Chilton Capital Management first reported a position in REGN in Q4 2015 and held it in 6 quarters. The position peaked at $206K in Q4 2015. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Chilton Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Chilton Capital Management sold 9 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $9.46K.
Chilton Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 6 quarters.
Chilton Capital Management's Regeneron Pharmaceuticals position peaked at $206K in Q4 2015.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Chilton Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.